Rizwan Khan, MD
Allergy & Immunology · Ithaca, NYNPI 1700864881
Payments from drug & device makers
Across 171 payments — averaging $20.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$826
- GSK$730
- Novartis$374
- Regeneron Healthcare Solutions, Inc.$203
- CSL Behring$202
- Pfizer$194
- plus $916 from 20 others
What the payments were for
- Consulting fees$160%
- Food & beverage$3,35297%
- Education$762%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $826 |
| GSK | 46 | $730 |
| Novartis | 15 | $374 |
| Regeneron Healthcare Solutions, Inc. | 9 | $203 |
| CSL Behring | 10 | $202 |
| Pfizer | 6 | $194 |
| Amgen | 6 | $159 |
| Sanofi | 7 | $136 |
| Teva Pharmaceuticals USA, Inc. | 8 | $110 |
| Boehringer Ingelheim | 5 | $73 |
| Aimmune Therapeutics, Inc. | 3 | $59 |
| Jubilant Hollisterstier LLC | 1 | $51 |
| Greer Laboratories, Inc. | 2 | $35 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $32 |
| Ionis Pharmaceuticals, Inc. | 1 | $32 |
| Genentech USA, Inc. | 1 | $32 |
| Shire North American Group Inc | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Biocryst US Sales Co., LLC | 1 | $22 |
| Grifols USA, LLC | 1 | $22 |
| Merck | 1 | $19 |
| Pharming Healthcare, Inc. | 1 | $18 |
| Optinose US, Inc. | 1 | $16 |
| ADMA Biomanufacturing LLC | 1 | $16 |
| Alk-abello, Inc | 1 | $12 |
| Kaleo, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,444 in reported general payments places this provider in the 50th percentile of 320 allergy & immunology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 36 | $275,487 |
| XolairOmalizumab | 33 | $103,651 |
| NucalaMepolizumab | 17 | $72,832 |
| Spiriva RespimatTiotropium Bromide | 56 | $48,133 |
| Dupixent SyringeDupilumab | 13 | $46,774 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $32,055 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $28,642 |
| Arnuity ElliptaFluticasone Furoate | 47 | $16,479 |
| Pulmicort FlexhalerBudesonide | 14 | $6,147 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $5,645 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $5,422 |
| AlvescoCiclesonide | 15 | $3,673 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $2,957 |
| Azelastine Hcl | 106 | $2,876 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $2,850 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $202 | $275,48736 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $730 | $155,429159 claims |
| Boehringer IngelheimSpiriva Respimat | $73 | $48,13356 claims |
| AstraZenecaPulmicort Flexhaler, Symbicort | $826 | $11,79239 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 320 allergy & immunology providers in New York.
Other allergy & immunology in Ithaca
- Peter DeaneRochester$3.7M
- Syed MustafaRochester$3.6M
- Golda HudesBronx$2.4M
- Arye RubinsteinBronx$1.1M
- Ujwala KazaNew York$1.1M
- Robert SporterNew York$980K
- Mili ShumWest Harrison$924K
- Paula BusseNew York$821K
- Gregory PuglisiPlainview$813K
- Stanley GoldsteinRockville Centre$653K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.